Bionano Genomics (BNGO)
Market Price (2/24/2026): $1.14 | Market Cap: $6.1 MilSector: Health Care | Industry: Health Care Equipment
Bionano Genomics (BNGO)
Market Price (2/24/2026): $1.14Market Cap: $6.1 MilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -73% | Weak multi-year price returns2Y Excs Rtn is -135%, 3Y Excs Rtn is -165% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -37 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -127% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -14% | |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 19% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -65%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -65% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -644% | ||
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 21% | ||
| Key risksBNGO key risks include [1] a significant "going concern" risk stemming from a limited cash runway and substantial unprofitability, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -73% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -135%, 3Y Excs Rtn is -165% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -37 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -127% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -14% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 19% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -65%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -65% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -644% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 21% |
| Key risksBNGO key risks include [1] a significant "going concern" risk stemming from a limited cash runway and substantial unprofitability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Bionano Genomics (BNGO) stock has lost about 35% since 10/31/2025 because of the following key factors:
1. Preliminary Financial Results Indicating Revenue Decline: Bionano Genomics reported preliminary unaudited financial results for the fourth quarter and full-year 2025 on January 12, 2026. The report indicated an expected decrease in total revenue year-over-year for both periods, with Q4 2025 revenue projected to decline by 2% to 4% and full-year 2025 revenue by 7% to 8% compared to the previous year. This sustained lack of robust top-line growth served as a negative signal for investors.
2. Continued Liquidity Concerns and Dilution Risk: Bionano Genomics continued to face liquidity concerns and the associated risk of shareholder dilution during this period. While the company completed a public offering in September 2025, generating approximately $10 million in gross proceeds through the sale of common stock and warrants, the ongoing need for capital to fund operations often leads to further equity offerings. This continuous potential for dilution can exert downward pressure on the stock price.
Show more
1. Preliminary Financial Results Indicating Revenue Decline: Bionano Genomics reported preliminary unaudited financial results for the fourth quarter and full-year 2025 on January 12, 2026. The report indicated an expected decrease in total revenue year-over-year for both periods, with Q4 2025 revenue projected to decline by 2% to 4% and full-year 2025 revenue by 7% to 8% compared to the previous year. This sustained lack of robust top-line growth served as a negative signal for investors.
2. Continued Liquidity Concerns and Dilution Risk: Bionano Genomics continued to face liquidity concerns and the associated risk of shareholder dilution during this period. While the company completed a public offering in September 2025, generating approximately $10 million in gross proceeds through the sale of common stock and warrants, the ongoing need for capital to fund operations often leads to further equity offerings. This continuous potential for dilution can exert downward pressure on the stock price.
Show more
Stock Movement Drivers
Fundamental Drivers
The -37.2% change in BNGO stock from 10/31/2025 to 2/23/2026 was primarily driven by a -35.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 2232026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.80 | 1.13 | -37.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 27 | 29 | 4.7% |
| P/S Multiple | 0.2 | 0.2 | -7.0% |
| Shares Outstanding (Mil) | 3 | 5 | -35.5% |
| Cumulative Contribution | -37.2% |
Market Drivers
10/31/2025 to 2/23/2026| Return | Correlation | |
|---|---|---|
| BNGO | -37.2% | |
| Market (SPY) | 0.0% | 52.8% |
| Sector (XLV) | 9.9% | 28.4% |
Fundamental Drivers
The -62.5% change in BNGO stock from 7/31/2025 to 2/23/2026 was primarily driven by a -49.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 2232026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.01 | 1.13 | -62.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 28 | 29 | 0.9% |
| P/S Multiple | 0.3 | 0.2 | -26.3% |
| Shares Outstanding (Mil) | 3 | 5 | -49.5% |
| Cumulative Contribution | -62.5% |
Market Drivers
7/31/2025 to 2/23/2026| Return | Correlation | |
|---|---|---|
| BNGO | -62.5% | |
| Market (SPY) | 8.3% | 16.0% |
| Sector (XLV) | 22.1% | 11.1% |
Fundamental Drivers
The -78.2% change in BNGO stock from 1/31/2025 to 2/23/2026 was primarily driven by a -73.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312025 | 2232026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.19 | 1.13 | -78.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 33 | 29 | -13.8% |
| P/S Multiple | 0.2 | 0.2 | -5.7% |
| Shares Outstanding (Mil) | 1 | 5 | -73.2% |
| Cumulative Contribution | -78.2% |
Market Drivers
1/31/2025 to 2/23/2026| Return | Correlation | |
|---|---|---|
| BNGO | -78.2% | |
| Market (SPY) | 14.4% | 16.7% |
| Sector (XLV) | 9.4% | 9.3% |
Fundamental Drivers
The -99.9% change in BNGO stock from 1/31/2023 to 2/23/2026 was primarily driven by a -99.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312023 | 2232026 | Change |
|---|---|---|---|
| Stock Price ($) | 1086.00 | 1.13 | -99.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 26 | 29 | 10.9% |
| P/S Multiple | 2.0 | 0.2 | -89.6% |
| Shares Outstanding (Mil) | 0 | 5 | -99.1% |
| Cumulative Contribution | -99.9% |
Market Drivers
1/31/2023 to 2/23/2026| Return | Correlation | |
|---|---|---|
| BNGO | -99.9% | |
| Market (SPY) | 74.1% | 24.5% |
| Sector (XLV) | 24.4% | 15.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BNGO Return | -3% | -51% | -87% | -85% | -91% | -25% | -100% |
| Peers Return | 13% | -41% | 7% | -32% | 6% | -6% | -52% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 84% |
Monthly Win Rates [3] | |||||||
| BNGO Win Rate | 17% | 42% | 33% | 25% | 33% | 0% | |
| Peers Win Rate | 62% | 32% | 50% | 42% | 47% | 30% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| BNGO Max Drawdown | -3% | -59% | -91% | -90% | -92% | -29% | |
| Peers Max Drawdown | -9% | -55% | -28% | -41% | -40% | -10% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: PACB, ILMN, TXG, A, TMO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/23/2026 (YTD)
How Low Can It Go
| Event | BNGO | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -99.2% | -25.4% |
| % Gain to Breakeven | 12257.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -79.6% | -33.9% |
| % Gain to Breakeven | 389.0% | 51.3% |
| Time to Breakeven | 271 days | 148 days |
| 2018 Correction | ||
| % Loss | -93.7% | -19.8% |
| % Gain to Breakeven | 1483.8% | 24.7% |
| Time to Breakeven | 459 days | 120 days |
Compare to PACB, ILMN, TXG, A, TMO
In The Past
Bionano Genomics's stock fell -99.2% during the 2022 Inflation Shock from a high on 2/16/2021. A -99.2% loss requires a 12257.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Bionano Genomics (BNGO)
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
AI Analysis | Feedback
- The Illumina for large-scale structural changes in DNA.
- If Illumina provides the alphabet of the genome, Bionano provides the blueprint of its architecture.
- The Foundation Medicine for structural genomics.
AI Analysis | Feedback
- Saphyr System: An instrument platform utilized for high-resolution optical genome mapping (OGM) to detect structural variants in the genome.
- OGM Reagents and Consumables: Kits and chips essential for preparing DNA samples and running OGM assays on the Saphyr system.
- Bionano Access and Solve Software: Proprietary software solutions for data analysis, visualization, and interpretation of OGM results.
- Clinical OGM Solutions: Specific OGM applications and assays designed for detecting structural variants in various clinical and research areas, including prenatal, postnatal, and cancer diagnostics.
AI Analysis | Feedback
Bionano Genomics (BNGO) develops and markets the Saphyr system, a platform for optical genome mapping (OGM) used for structural variant detection in genomics research and clinical applications. As such, the company primarily sells its products and services to other organizations rather than directly to individuals.
Bionano Genomics does not publicly disclose a list of its specific major customers by name, nor does it typically identify individual companies (with stock symbols) as major customers. This is common practice for companies selling scientific instrumentation and consumables to a broad base of research and clinical laboratories. Instead, their customer base consists of various types of institutions and organizations globally.
The primary categories of customers that Bionano Genomics serves include:
- Academic and Research Institutions: This category includes universities, academic medical centers, and government-funded research laboratories worldwide. These institutions utilize the Saphyr system for basic science research, translational studies, and large-scale genomics projects aimed at understanding diseases and biological processes.
- Clinical Diagnostic Laboratories: Both private and public clinical labs adopt Bionano's technology to enhance their diagnostic and prognostic testing capabilities for various conditions, including genetic disorders, rare diseases, and different types of cancer. These labs aim to integrate OGM into their routine clinical workflows.
- Biopharmaceutical Companies: Companies engaged in drug discovery, development, and therapeutic research, especially those focused on genomics, gene therapy, and precision medicine, utilize the Saphyr system for detailed genomic analysis critical to their R&D pipelines.
- Contract Research Organizations (CROs): CROs that offer genomics services to pharmaceutical, biotechnology, and academic clients may incorporate Bionano's technology to provide advanced structural variant analysis as part of their service offerings.
AI Analysis | Feedback
null
AI Analysis | Feedback
Erik Holmlin, PhD, President and Chief Executive Officer
Dr. Erik Holmlin has served as the CEO and President of Bionano Genomics since January 2011. He has over two decades of experience in the life science and healthcare industries. Dr. Holmlin founded GeneOhm Sciences, Inc., in 2001, and orchestrated its acquisition by Becton Dickinson in 2006. He also served as an Entrepreneur in Residence at Domain Associates, LLC, a leading life-science venture capital firm. His prior experience includes CEO at GenVault Corporation, Chief Commercial Officer at Exiqon A/S, and Vice President of Marketing and Development at Becton Dickinson.
Christopher Stewart, Former Chief Financial Officer
Christopher Stewart served as Bionano Genomics' Chief Financial Officer from September 2020 to September 2023. He brings over 20 years of financial management experience to his role. Prior to Bionano, he was Head of the Maxwell Ultracapacitors business unit at Tesla after Maxwell Technologies was acquired by Tesla. He also served as Vice President of Finance & Information Technology at Maxwell Technologies (a public company), Vice President of Finance at Entropic Communications (a public company), and Chief Financial Officer of V-ENABLE (now xAD), a leader in targeted mobile advertising. Stewart has demonstrated extensive mergers and acquisition experience.
Mark Oldakowski, Chief Operating Officer
Mark Oldakowski has a 20-year history of success in developing systems for the life sciences and medical device industries. Before joining Bionano Genomics, he led a global team at Brooks Life Science Systems in the development of sample analyzers, high-throughput screening solutions, and biobank systems. He also held roles at Affymetrix, where he launched an array platform widely used for genomics applications, Siemens Healthcare Diagnostics, and Life Technologies (formerly Applied Biosystems), where he was involved in developing systems for real-time PCR, sequencing, and sample preparation.
Alka Chaubey, PhD, FACMG, Chief Medical Officer
Dr. Alka Chaubey joined Bionano as its first Chief Medical Officer, effective August 31, 2020. She is double board-certified in clinical cytogenetics/genomics and clinical molecular genetics/genomics by the American Board of Medical Genetics and Genomics (ABMGG). Dr. Chaubey has nearly 20 years of scientific and clinical experience, including serving as the Head of Cytogenomics for PerkinElmer Genomics and for Vanadis, where she led the development and launch of several innovative products. She was also the Director of the Cytogenomics Laboratory at the Greenwood Genetic Center.
Jason Priar, Chief Commercial Officer
Jason Priar joined Bionano Genomics as Chief Commercial Officer in June 2021. He is a seasoned sales leader with experience scaling businesses from early stage to hundreds of millions in revenue. His background includes sales leadership positions at GeneDx, Sema4, and PerkinElmer Genomics, where he was responsible for sales, marketing, customer support, and managed care across various regions. Under his leadership at GeneDx, revenue grew from $8 million to over $225 million.
AI Analysis | Feedback
Key Risks to Bionano Genomics (BNGO)
-
Cash and Capital / Profitability: Bionano Genomics faces significant financial risks due to its substantial accumulated deficit, reported to be over $703.2 million as of June 30, 2025, and continued negative cash flow from operations. The company's cash and equivalents of $31.8 million at the end of Q3 2025 provide a cash runway only into the third quarter of 2026, making it a "going concern" risk. Despite efforts to reduce operating expenses and improve gross margins, the company is not yet profitable, with a forecasted earnings per share (EPS) loss of approximately -$6.23 for fiscal year 2025. This ongoing cash burn necessitates a reliance on equity to fund operations, leading to historical and potential future share dilution.
-
Slow Adoption of Optical Genome Mapping (OGM) Technology / Revenue Challenges: The growth of Bionano's business is heavily dependent on the adoption and utilization of its Optical Genome Mapping (OGM) systems and associated high-margin consumables. However, the company has experienced slow growth in its installed base, with only 7 new OGM systems installed in Q3 2025, resulting in a net increase of just 3 to a total of 384 systems. This slow adoption limits the pool of customers purchasing consumables and contributes to challenges in revenue generation, including a reported decline in total revenue and flowcell sales volume. Analysts also point to a potentially small total addressable market (TAM) and a market not fully ready to embrace OGM technology, which could hinder the company's ability to create shareholder value. Additionally, slow clinical guideline adoption and reimbursement uncertainty threaten revenue acceleration.
-
Technological Risk / Competition: Bionano Genomics operates in a rapidly evolving genomics landscape, facing high technological risk from both current and potential competitors. Competitive pressures, along with lagging research budgets and slow global market integration, could limit the company's growth prospects even as it attempts to increase software and consumables adoption.
AI Analysis | Feedback
The rapid advancements and increasing adoption of long-read sequencing technologies, particularly from companies like Pacific Biosciences (PacBio) and Oxford Nanopore Technologies (ONT). These platforms are continuously improving their ability to detect a broad spectrum of structural variants (SVs) with high accuracy, increasing throughput, and decreasing cost per genome. As long-read sequencing becomes more cost-effective and integrated into clinical and research workflows for comprehensive genome analysis, it directly encroaches upon Bionano Genomics' core value proposition of identifying large structural variants, potentially diminishing the unique necessity or market share of Optical Genome Mapping (OGM) as a standalone or primary solution for SV detection.
AI Analysis | Feedback
The addressable markets for Bionano Genomics' (BNGO) main products and services are substantial, primarily driven by the demand for advanced genomic analysis in research and clinical diagnostics.
Optical Genome Mapping (OGM)
- The global optical genome mapping market was valued at approximately USD 131.50 million in 2023. It is estimated to reach USD 883.50 million by 2032, demonstrating a compound annual growth rate (CAGR) of 24.10% during the forecast period from 2024 to 2032.
- North America held the largest share of the global optical genome mapping market in 2023, accounting for 45.07%.
- Bionano's management has previously estimated its total addressable market for optical genome mapping capabilities to be USD 10 billion.
Genetic Testing and Diagnostic Services
- Rare Disease Genetic Testing Market: The global rare disease genetic testing market is projected to grow from USD 918.94 million in 2023 to approximately USD 3,051.6 million by 2032, at a CAGR of 13.1% during the forecast period from 2022 to 2032.
-
Prenatal and Newborn Genetic Testing Market: The global prenatal and newborn genetic testing market was valued at USD 8.1 billion in 2024. This market is anticipated to grow to USD 26.8 billion by 2034, with a CAGR of 12.8%.
- Specifically, the U.S. prenatal and newborn genetic testing market reached USD 3.8 billion in 2024.
- Another report projects the global prenatal testing market to grow from USD 9.8 billion in 2022 to USD 19.8 billion in 2028, at a CAGR of 12.6%.
- First-line genetic testing for Autism Spectrum Disorder (ASD) and other Neurodevelopmental Disorders (NDDs) (U.S.): Bionano Genomics has estimated the serviceable addressable market (SAM) in the United States for its Lineagen FirstStepDx PLUS testing to be between USD 1.7 billion and USD 2.2 billion.
AI Analysis | Feedback
Bionano Genomics (BNGO) is positioning itself for future revenue growth over the next two to three years through several key drivers, as indicated by recent company reports and analyst insights:
- Increased Utilization of Optical Genome Mapping (OGM) Systems and Consumables: Bionano is strategically shifting its focus from merely increasing the installed base of its Saphyr systems to driving higher utilization among existing and new "routine users." This strategy aims to boost the sales of high-margin consumables, such as nanochannel array flowcells, which are directly linked to the number of genomes analyzed. For example, flowcell sales increased by 17% in Q2 2025 year-over-year, and consumables and software revenue grew 16% in the same quarter, representing 73% of product revenue. The company anticipates the installed base of OGM systems to reach 325 by the end of 2023, and has raised its expectations for new OGM installations in 2025 to 20-25 systems.
- Expansion of VIA Software Platform Adoption: The VIA software is considered a crucial component of Bionano's digital pathology strategy and a gold standard for copy number variation (CNV) analysis for microarrays and sequencing. Bionano is actively driving the adoption of its VIA software, which streamlines the visualization, interpretation, annotation, and reporting of genetic variants. This expansion is expected to drive recurring revenue as customers increasingly integrate VIA into their genomic analysis workflows, even for data from other long-read sequencing technologies.
- Favorable Reimbursement Landscape and Clinical Market Penetration: The issuance of Category I CPT codes for optical genome mapping (OGM), particularly for constitutional disorders and hematologic malignancies, is a significant catalyst for future revenue growth. These codes are expected to pave the way for more routine use of OGM in cytogenetics by facilitating reimbursement, making the technology more accessible and attractive to clinical laboratories. The company believes this progress will accelerate OGM adoption in the clinical market, potentially displacing older methods.
- Technological Enhancements and Workflow Improvements for OGM: Continuous innovation and improvements to the OGM workflow are expected to drive adoption and utilization. The acquisition of Purigen Biosystems, for instance, is anticipated to accelerate OGM adoption by enhancing Bionano's ultra-high molecular weight (UHMW) DNA sample preparation workflow. Additionally, the positive reception and first-wave deployments of the Stratus compute are expected to foster further growth in user numbers across the United States and Europe by making OGM easier to implement and use, and capable of processing substantially more samples.
AI Analysis | Feedback
Share Issuance
- In January 2021, Bionano Genomics announced the pricing of an underwritten public offering of 33,333,350 shares of its common stock at $6.00 per share, expecting to generate approximately $200 million in gross proceeds.
- In October 2023, Bionano Genomics completed an $80 million financing round and ended the year with $102.3 million in cash and securities.
- Bionano Genomics completed a registered direct offering in January 2025, raising $10 million through the sale of 39,682,540 shares of common stock and warrants at $0.252 per share, with potential for an additional $10 million if warrants are fully exercised. In September 2025, the company closed another public offering, raising approximately $10 million in gross proceeds from 5,000,000 shares at $2.00 per share and accompanying warrants, with the potential for an additional $20 million if warrants are fully exercised.
Outbound Investments
- In August 2020, Bionano Genomics acquired Lineagen Inc., a genetic diagnostic company specializing in pediatric neurodevelopmental disorders, for approximately $9.6 million. The consideration included 6,167,510 shares of Bionano's common stock, approximately $1.7 million in cash, and the assumption of about $2.9 million in liabilities. Bionano also paid approximately $1.1 million to satisfy outstanding principal and accrued interest of a Paycheck Protection Program loan issued to Lineagen.
Capital Expenditures
- Bionano Genomics' cash flow statements indicate capital expenditures of approximately -$2.4 million in 2020.
- In 2021, capital expenditures were approximately -$278.1 million.
- For 2024, Bionano's free cash flow was -$70.77 million, and operating cash flow was -$70.67 million, with proceeds from offerings generally intended for general corporate purposes, including capital expenditures.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Bionano Genomics Earnings Notes | 12/16/2025 | |
| How Low Can Bionano Genomics Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to BNGO.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | ABT | Abbott Laboratories | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 5.5% | 5.5% | -1.0% |
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -15.6% | -15.6% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 19.4% | 19.4% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 15.3% | 15.3% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -42.4% | -42.4% | -42.4% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 69.72 |
| Mkt Cap | 10.4 |
| Rev LTM | 2,493 |
| Op Inc LTM | 390 |
| FCF LTM | 531 |
| FCF 3Y Avg | 330 |
| CFO LTM | 608 |
| CFO 3Y Avg | 420 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1.3% |
| Rev Chg 3Y Avg | 2.8% |
| Rev Chg Q | 5.0% |
| QoQ Delta Rev Chg LTM | 1.2% |
| Op Mgn LTM | 0.6% |
| Op Mgn 3Y Avg | -9.2% |
| QoQ Delta Op Mgn LTM | 2.5% |
| CFO/Rev LTM | 19.3% |
| CFO/Rev 3Y Avg | 12.4% |
| FCF/Rev LTM | 15.3% |
| FCF/Rev 3Y Avg | 8.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 10.4 |
| P/S | 4.0 |
| P/EBIT | 19.0 |
| P/E | 10.7 |
| P/CFO | 17.3 |
| Total Yield | 0.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.4% |
| D/E | 0.2 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -18.6% |
| 3M Rtn | -15.4% |
| 6M Rtn | 12.6% |
| 12M Rtn | -0.0% |
| 3Y Rtn | -48.4% |
| 1M Excs Rtn | -19.4% |
| 3M Excs Rtn | -13.0% |
| 6M Excs Rtn | 6.8% |
| 12M Excs Rtn | -15.4% |
| 3Y Excs Rtn | -115.5% |
Price Behavior
Price Behavior
| Market Price | $1.13 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 09/21/2018 | |
| Distance from 52W High | -78.9% | |
| 50 Days | 200 Days | |
| DMA Price | $1.43 | $2.48 |
| DMA Trend | down | down |
| Distance from DMA | -21.2% | -54.5% |
| 3M | 1YR | |
| Volatility | 52.6% | 93.4% |
| Downside Capture | 413.88 | 237.83 |
| Upside Capture | 118.75 | 45.84 |
| Correlation (SPY) | 53.2% | 17.2% |
BNGO Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.32 | 2.54 | 2.61 | 1.19 | 0.79 | 1.48 |
| Up Beta | 7.16 | 6.77 | 4.45 | 0.69 | 0.80 | 1.13 |
| Down Beta | 1.10 | 1.21 | 1.88 | 1.99 | 0.07 | 0.53 |
| Up Capture | 183% | 71% | 133% | -23% | 34% | 27% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 6 | 14 | 22 | 52 | 101 | 296 |
| Down Capture | 624% | 387% | 291% | 211% | 151% | 113% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 12 | 24 | 35 | 67 | 132 | 423 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BNGO | |
|---|---|---|---|---|
| BNGO | -78.3% | 93.4% | -1.21 | - |
| Sector ETF (XLV) | 9.2% | 17.3% | 0.35 | 9.8% |
| Equity (SPY) | 12.8% | 19.4% | 0.50 | 17.3% |
| Gold (GLD) | 79.1% | 25.7% | 2.25 | 12.0% |
| Commodities (DBC) | 7.7% | 16.9% | 0.27 | 9.8% |
| Real Estate (VNQ) | 6.6% | 16.7% | 0.21 | 11.3% |
| Bitcoin (BTCUSD) | -30.9% | 44.9% | -0.69 | 17.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BNGO | |
|---|---|---|---|---|
| BNGO | -83.5% | 93.4% | -1.49 | - |
| Sector ETF (XLV) | 8.1% | 14.5% | 0.37 | 24.4% |
| Equity (SPY) | 13.2% | 17.0% | 0.61 | 36.8% |
| Gold (GLD) | 23.6% | 17.1% | 1.12 | 6.9% |
| Commodities (DBC) | 10.7% | 19.0% | 0.45 | 8.5% |
| Real Estate (VNQ) | 5.1% | 18.8% | 0.18 | 31.3% |
| Bitcoin (BTCUSD) | 6.7% | 57.1% | 0.34 | 22.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BNGO | |
|---|---|---|---|---|
| BNGO | -55.9% | 194.6% | -0.07 | - |
| Sector ETF (XLV) | 11.3% | 16.5% | 0.57 | 9.4% |
| Equity (SPY) | 15.7% | 17.9% | 0.75 | 12.5% |
| Gold (GLD) | 15.1% | 15.6% | 0.81 | 4.6% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | 3.9% |
| Real Estate (VNQ) | 6.9% | 20.7% | 0.30 | 10.6% |
| Bitcoin (BTCUSD) | 67.8% | 66.8% | 1.07 | 7.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/13/2025 | 3.4% | 1.4% | 6.8% |
| 8/14/2025 | -5.3% | 28.7% | -13.7% |
| 3/31/2025 | 11.1% | 5.7% | 43.0% |
| 11/13/2024 | -7.6% | -24.4% | -13.4% |
| 8/7/2024 | -6.7% | -2.5% | 2.7% |
| 3/5/2024 | 1.7% | -10.9% | -17.1% |
| 11/8/2023 | -2.2% | 0.7% | 8.1% |
| 8/9/2023 | -3.4% | -25.3% | -18.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 8 | 7 |
| # Negative | 12 | 11 | 12 |
| Median Positive | 2.6% | 5.7% | 8.1% |
| Median Negative | -7.1% | -11.9% | -17.7% |
| Max Positive | 11.1% | 43.8% | 43.0% |
| Max Negative | -32.3% | -57.7% | -75.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/05/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 03/01/2022 | 10-K |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.